Explore a selection of the 200+ articles we've published since our founding
Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies
JCO Precision Oncology (April 2017)
NGS identifies alterations that may be pharmacologically tractable in most patients with lymphoid malignancies, albeit with drugs that have usually been developed in the context of solid tumors.
Journal of the National Comprehensive Cancer Network (February 2016)
This exceptional response to pazopanib treatment suggests that a subset of patients with angiosarcoma with genomic alterations in vascular signaling genes may respond well to pazopanib.
Patient-derived xenotransplants (PDX) can recapitulate the genetic driver landscape of acute leukemias
Leukemia (January 2017)
These data emphasize the importance of genomic profiling of PDX and patient samples to ensure concordance before performing mechanistic or therapeutic studies.
Identification of a novel fusion TBL1XR1–PDGFRB in a patient with acute myeloid leukemia harboring the DEK–NUP214 fusion and clinical response to dasatinib
Leukemia & Lymphoma (May 2017)
In this case study, we describe a novel PDGFRB rearrangement, TBL1XR1–PDGFRB, in a patient with AML with recurrent genetic abnormality.
Annals of Oncology (2016)
In this review, the role of somatic BRCA mutations and BRCA methylation in ovarian cancer is discussed alongside the challenges that need to be addressed if the full potential of these markers of HRD is to be utilised in clinical practice.
Journal of Neuro-Oncology (2016)
Genomic research of high-grade glioma (HGG) has revealed complex biology with potential for therapeutic impact.
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
Annals of Oncology (August 2017)
Obtaining a metastatic tissue biopsy can be challenging, and analysis of circulating tumor DNA (ctDNA) from blood may provide a minimally invasive alternative.
CD74-ROS1 fusion in NSCLC detected by hybrid capture-based tissue genomic profiling and ctDNA assays
Journal of Thoracic Oncology (2017)
A case study of a patient with metastatic NSCLC with a ROS1 fusion detected by tissue and blood hybrid capture–based assays but not by another circulating tumor DNA (ctDNA) assay.
The Lancet Oncology (2016)
The ARIEL2 study assessed the ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor.
Clinical Cancer Research (2017)
A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer.